SpringerProtocols: Abstract: Enzyme-Prodrug Systems: Thymidine Phosphorylase/5′-Deoxy-5-Fluorouridine

Enzyme-Prodrug Systems: Thymidine Phosphorylase/5′-Deoxy-5-Fluorouridine

By: Alexandre Evrard², Joseph Ciccolini³, Pierre Cuq², Jean-Paul Cano²

Abstract

Full Text

Download PDF (189K)

Thymidine phosphorylase (E.C. 2.4.2.4) (TP), also described as the angiogenic platelet-derived endothelial cell growth factor (PD-ECGF) (1–4), is a homodimeric enzyme with a monomeric molecular mass of about 55 kDa (5,6) that phosphorolytically cleaves thymidine to yield thymine and deoxyribose-1-phosphate (dR-1-P) (7,8). TP is expressed in various human cells and tissues and plays a role in plasma thymidine homeostasis (9–11). The levels of expression in different human tissues can vary up to 15-fold (12). Moreover, TP levels are increased in several types of malignant tumors when compared to the non-neoplastic regions of these tissues (13) and also in the plasma from tumor-bearing animals and cancer patients (14).

Affiliation(s): (2) Department of Toxicology, Faculty of Pharmacy, University of Montpellier, Montpellier, France
(3) Department of Pharmacokinetics and Toxicokinetics, Faculty of Pharmacy, University of Aix-Marseille, Marseille, France

Book Title: Suicide Gene Therapy: Methods and Reviews

Series: Methods in Molecular Medicine | Volume: 90 | Pub. Date: Nov-04-2003 | Page Range: 263-278 | DOI: 10.1385/1-59259-429-8:263

Subject: Genetics/Genomics

References

Download References

1.	Ishikawa, F, Miyazono, K., Hellman, U., et al. (1989) Identification of angiogenic activity and the cloning and expression of platelet derived endothelial cell growth factor. Nature 338, 557–562.

2.	Moghaddam, A. and Bicknell, R. (1992) Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31, 12,141–12,146.

3.	Sumizawa, T., Furukawa, T., Haraguchi, M., et al. (1993) Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. 114, 9–14.

4.	Miyadera, K., Sumizawa, T., Haraguchi, M., et al. (1995) Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55, 1687–1690.

5.	Desgranges, C., Razaka, G., and Rabaud, H. (1981) Catabolism of thymidine in human blood platelets—purification and properties of thymidine phosphorylase. Biochim. Biophys. Acta 654, 211–218.

6.	Miyazono, K., Okabe, T., Urabe, A., Takaku, F., and Heldin, C.H. (1987) Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 262, 4098–4103.

7.	Friedkin, M. and Roberts, D. (1953) The enzymatic synthesis of nucleosides. Thymidine phosphorylase in mammalian tissue. J. Biol. Chem. 207, 245–256.

8.	Krenitsky T. A. (1968) Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylase. J. Biol. Chem. 243, 2871–2875.

9.	Zimmerman, M. and Seidenberg, J. (1964) Deoxyribosyl transfer. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissue. J. Biol. Chem. 230, 2618–2621.

10.	Shaw, J., Smillie, R. H., Miller, A. E., and MacPhee, D. G. (1988) The role of blood platelets in nucleoside metabolism: regulation of thymidine phosphorylase. Mutat. Res. 200, 117–131.

11.	Fox, S. B., Moghaddam, A., Westwood, M., et al. (1995) Platelet-derived endothelial cell growth factor thymidine phosphorylase expression in normal tissues-an immunohistochemical study. J. Pathol. 176, 183–190.

12.	Yoshimura, A., Kuwazuru, Y., Furukawa, T., Yoshida, H., Yamada, K., and Akiyama, S. (1990) Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim. Biophys. Acta 1034, 107–113.

13.	Obrien, T. S., Fox, S. B., Dickinson, A. J., et al. (1996) Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56, 4799–4804.

14.	Luccioni, C., Beaumatin, J., Bardot, V., and Lefrancois, D. (1994) Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int. J. Cancer 58, 517–522.

15.	Ciccolini, J., Peillard, L., Evrard, A., et al. (2000) Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin. Cancer Res. 6, 1529–1535.

16.	Ackland, S. P. and Peters, G. J. (1999) Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist. Updates 2, 205–214.

17.	Rustum, Y. M., Harstrick, A., Cao, S., et al. (1997) Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15, 389–400.

18.	Sobrero, A. F., Aschele, C., and Bertino, J. R. (1997) Fluorouracil in colorectal cancer—A tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15, 368–381.

19.	Schwartz, E. L., Baptiste, N., Wadler, S., and Makower, D. (1995) Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem. 270, 19,073–19,077.

20.	Haraguchi, M., Furukawa, T., Sumizawa, T., and Akiyama, S. (1993) Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor factor to pyrimidine antimetabolites. Cancer Res. 53, 5680–5682.

21.	Patterson, A.V., Zhang, H., Moghaddam, A., et al. (1995) Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-desoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer 72, 669–675.

22.	Evrard, A., Cuq, P., Robert, B., Vian, L., Pèlegrin, A., and Cano, J. P. (1999) Enhancement of 5-fluorouracil cytotoxicity by human thymidine phosphorylase expression in cancer cells: in vitro and in vivo study. Int. J. Cancer 80, 465–470.

23.	Kato, Y., Matsukawa, S., Muraoka, R., and Tanigawa, N. (1997) Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br. J. Cancer 75, 506–511.

24.	Evrard, A., Cuq, P., Ciccolini, J., Vian, L., and Cano, J.P. (1999) Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br. J. Cancer 80, 1726–1733.

25.	Morita, T., Matsuzaki, A. and Tokue, A. (2001) Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int. J. Cancer 92, 451–456.

26.	Fick, J., Barker, F. G. II, Dazin, P., Westphale, E. M., Beyer, E. C., and Israel, M. A. (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92, 11,071–11,075.

27.	Denning, C. and Pitts, J. D. (1997) Bystander effect of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther. 8, 1825–1835.

28.	Lonn, U., Lonn, S., Nylen, U., and Winblad, G. (1989) 5-Fluoropyrimidine-induced DNA damage in human colonadenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole. Cancer Res. 49, 1085–1089.

29.	Grem, J. L. and Fischer, P. H. (1986) Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res. 46, 6191–6199.

30.	Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.

31.	Ciccolini, J., Peillard, L., Aubert, C., Formento, P., Milano, G., and Catalin, J. (2000) Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. Fundam. Clin. Pharmacol. 14, 147–154.

Comments (Loading...)

Post comment/View all comments